American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside

by admin October 10, 2024
October 10, 2024
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US related to its discontinued heartburn medication, Zantac.

The lawsuits alleged that the drug, which was pulled from the market, caused cancer.

The settlement addresses about 93% of the cases faced by GSK, accounting for approximately 80,000 claimants.

In addition to this major settlement, GSK has agreed to pay an additional $70 million (€64m) to settle whistleblower claims brought by US-based independent laboratory Valisure.

The stock rose 6% in early London trading, reversing what had been a drop of 4.2% in the last 12 months.

Settlement in the best long-term interests of shareholders: GSK

In a statement following the announcement, GSK reiterated its stance on the scientific evidence regarding Zantac and outlined that the settlement will remove significant financial uncertainty.

While the scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, GSK strongly believes that these settlements are in the best long-term interests of the company and its shareholders as they remove significant financial uncertainty, risk, and distraction associated with protracted litigation.

GSK said it expects to take an additional charge of £1.8bn (€2.15bn) in its Q3 results of 2024 to account for the settlements, which include the State Courts Settlement, the Qui Tam Settlement, and the remaining 7% of pending cases.

Despite the hefty payout, GSK stated that these settlements would not impact its growth agenda or R&D investments, with costs being covered by existing resources.

Settlement to remove drag on GSK’s share price: Analysts

For GSK shareholders, this settlement marks a significant relief.

According to John Murphy of Bloomberg Intelligence, the resolution “lifts a major investor concern and allows the shares to trade on fundamentals, suggesting upside given GSK’s current significant discount to peers across a range of earnings multiples.”

The Zantac litigation had loomed heavily over GSK’s stock, contributing to underperformance compared to its competitors.

Analysts at Jefferies noted that GSK’s stock is likely to “uptick” by around 10%, now that much of the uncertainty surrounding the Zantac lawsuits has been lifted.

Jefferies had estimated the settlement to fall between $2 billion and $3.5 billion, with the final amount nearing the lower end of this range, described as “the best-case scenario” by Peter Welford, an analyst at the brokerage.

Positive long-term outlook despite lingering risks

Shore Capital analysts echoed the sentiment that GSK’s shares have suffered due to the risks tied to the Zantac litigation.

GSK’s desire to settle cases comes not from any legal or scientific merit but is in the best long-term interests of shareholders and to avoid any further distraction or financial uncertainty that comes with letting litigation continue to protract.

Before the settlement, market analysts like Sean Conroy from Shore Capital believed that GSK’s stock price had already factored in up to $30 billion in potential liabilities, further dragging down the company’s valuation.

UBS analysts, led by Jo Walton, noted the 7% of plaintiffs who are yet to settle with GSK could still cause problems for the British firm.

GSK’s settlement saw it reach an agreement with the 10 largest law firms handling Zantac claims while the remaining lawsuits are being handled by smaller firms. 

However, with much of the litigation risk resolved, analysts predict an improvement in GSK’s share performance in the coming months.

The post GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Wolfe Research downgrades Otis: is the elevator stock heading down?
next post
Celsius (CELH) stock divergence points to a comeback

Related Posts

ServiceNow stock is severely overvalued – rating downgrade

September 26, 2024

Coinbase stock has 2 catalysts: is the CONY...

October 15, 2024

From Bunge’s Viterra deal to Shein’s IPO: US-China...

May 3, 2025

US spot Bitcoin ETFs extend negative streak with...

March 1, 2025

Long US100: bullish breakout from descending channel with...

January 22, 2025

Citigroup shifts compliance work for 800 staff after...

September 16, 2024

TSMC Q4 revenue jumps 34% to $26B, beating...

January 10, 2025

Congress approved a TikTok ban. Why it could...

April 27, 2024

How on-time rent payments can help ‘credit invisible’...

July 19, 2024

Asian stocks close mixed: Hang Seng slips 0.4%,...

April 28, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • GMS stock jumps 29% on takeover interest from Home Depot, QXO, analysts raise PTs

      June 22, 2025
    • Japan’s rice price surge: what’s driving it and why it could spark a political crisis

      June 22, 2025
    • BofA raises STOXX 600 target amid resilient global growth, warns on Mideast risks

      June 22, 2025
    • Palantir co-founder: US must prevent Iranian nukes

      June 22, 2025
    • Fed governor Waller advocates for July rate cut amid tariff, labor market outlook

      June 21, 2025

    Categories

    • Business (3,209)
    • Investing (2,537)
    • Latest News (2,000)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved